BeStock  
Stocks › Biotechnology › SLS

Sellas Life Sciences SLS

US equityMarket cap rank #2495Biotechnology
$13.66 −$1.20 (-8.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $14.21 +4.03%
Open$14.98
Prev close$14.86
Day range$13.39 – $15.19
Volume15.48M
Market cap$2.78B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$11.31M-59.7% YoY
Net profit-$10.09M-48.6% YoY
Diluted EPS-$0.05+16.7% YoY
Free cash flow-$5.94M+16.0% YoY
Operating cash flow-$5.94M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-6.7MDec '24$-5.8MMar '25$-6.6MJun '25$-6.8MSep '25$-7.7MDec '25$-8.4MMar '26$-9.6MJun '26$-10.1MSep '26

Diluted EPS by quarter

-0.08Dec '24-0.07Mar '25-0.07Jun '25-0.06Sep '25-0.05Dec '25-0.05Mar '26-0.05Jun '26-0.05Sep '26

Free cash flow by quarter

$-7.2MDec '24$-9.1MMar '25$-7.3MJun '25$-7.1MSep '25$-4.9MDec '25$-8.8MMar '26$-7.6MJun '26$-5.9MSep '26

Annual revenue

$1.9MFY20$7.6MFY21$1.0MFY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-40.3%
Return on assets-37.1%
Return on invested capital-44.2%
Current ratio14.92
Liabilities / assets6.6%
Cash & investments$134.71M
Total debt$0.00
Net cash (debt)$134.71M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $11.31M $10.63M $9.25M $28.27M $8.26M
Selling and Admin Expenses $4.28M $4.36M $4.12M $12.25M $3.53M
-General & Admin Expense $4.28M $4.36M $4.12M $12.25M $3.53M
Research & Development $7.03M $6.27M $5.13M $16.02M $4.73M
Operating Profit -$11.31M -$10.63M -$9.25M -$28.27M -$8.26M
Net Non-Operating Interest Income (Expense) $1.22M $1.02M $845,000.00 $1.41M $597,000.00
Non-Operating Interest Income $1.22M $1.02M $845,000.00 $1.41M $597,000.00
Pretax Profit -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Net Profit -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Profit from Continuing Operations -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Net Income to Parent Company -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Net Income to Common Stockholders -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Basic EPS -$0.05 -$0.05 -$0.05 -$0.25 -$0.05
Diluted EPS -$0.05 -$0.05 -$0.05 -$0.25 -$0.05

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $141.09M $145.38M $114.18M $78.35M $78.35M
Total Current Assets $138.57M $142.51M $111.17M $75.21M $75.21M
Cash and Cash Equivalents & Short-Term Investments $134.71M $138.34M $107.10M $71.79M $71.79M
-Cash and Cash Equivalents $134.71M $138.34M $107.10M $71.79M $71.79M
Prepaid Assets $3.46M $4.06M $3.97M $3.10M $3.10M
Restricted Cash $100,000.00 $100,000.00 $100,000.00 $100,000.00 $100,000.00
Other Current Assets $303,000.00 – – $223,000.00 $223,000.00
Total Non-Current Assets $2.52M $2.88M $3.01M $3.13M $3.13M
Net PPE $578,000.00 $710,000.00 $839,000.00 $963,000.00 $963,000.00
-Gross PPE $578,000.00 $710,000.00 $839,000.00 $963,000.00 $963,000.00
Goodwill and Other Intangible Assets $1.91M $1.91M $1.91M $1.91M $1.91M
-Goodwill $1.91M $1.91M $1.91M $1.91M $1.91M
Other Non-Current Assets $25,000.00 $253,000.00 $255,000.00 $257,000.00 $257,000.00
Total Liabilities $9.29M $7.73M $6.77M $7.47M $7.47M
Total Current Liabilities $9.29M $7.57M $6.46M $7.02M $7.02M
Payables $2.09M $3.09M $3.63M $2.95M $2.95M
-Accounts Payable $2.09M $3.09M $3.63M $2.95M $2.95M
Current Accrued Expenses $4.94M $2.69M $1.61M $1.73M $1.73M
Short-Term Debt and Capital Lease Obligation $599,000.00 $580,000.00 $562,000.00 $544,000.00 $544,000.00
-Current Capital Lease Obligation $599,000.00 $580,000.00 $562,000.00 $544,000.00 $544,000.00
Other Current Liabilities $87,000.00 $58,000.00 $24,000.00 $42,000.00 $42,000.00
Total Non-Current Liabilities $0.00 $157,000.00 $309,000.00 $457,000.00 $457,000.00
Long Term Debt and Capital Lease Obligation $0.00 $157,000.00 $309,000.00 $457,000.00 $457,000.00
-Long Term Capital Lease Obligation $0.00 $157,000.00 $309,000.00 $457,000.00 $457,000.00
Total Equity $131.81M $137.66M $107.41M $70.87M $70.87M
Stockholders' Equity $131.81M $137.66M $107.41M $70.87M $70.87M
Capital Stock $20,000.00 $20,000.00 $18,000.00 $15,000.00 $15,000.00
-Common Stock $20,000.00 $20,000.00 $18,000.00 $15,000.00 $15,000.00
Additional Paid-In Capital $434.88M $430.64M $390.79M $345.84M $345.84M
Retained Earnings -$303.09M -$293.00M -$283.40M -$274.99M -$274.99M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$5.94M -$7.59M -$8.85M -$28.39M -$4.92M
Net cash flow from continuing operations -$5.94M -$7.59M -$8.85M -$28.39M -$4.92M
Net Income from Continuing Operations -$10.09M -$9.61M -$8.41M -$26.86M -$7.66M
Other Non-Cash Items $152,000.00 $154,000.00 $153,000.00 $597,000.00 $154,000.00
Change in Working Capital $2.07M $848,000.00 -$1.39M -$4.08M $2.14M
-Change in Prepaid Assets $527,000.00 -$88,000.00 -$652,000.00 -$968,000.00 $1.09M
-Change in Payables and Accrued Expense $1.70M $1.10M -$579,000.00 -$2.48M $1.21M
-Change in Other Current Liabilities -$158,000.00 -$159,000.00 -$159,000.00 -$635,000.00 -$159,000.00
Financing Cash Flow $2.31M $38.83M $44.15M $86.30M $32.39M
Net Cash Flow from Continuing Financing Activities $2.31M $38.83M $44.15M $86.30M $32.39M
Net Common Stock Issuance $0.00 $0.00 $0.00 $23.05M $0.00
Proceeds from Stock Option Exercised $2.31M $38.83M $44.15M $63.77M $32.92M
Ending Cash Balance $134.81M $138.44M $107.20M $71.89M $71.89M
Net Change in Cash -$3.63M $31.25M $35.30M $57.91M $27.47M
Beginning Cash Balance $138.44M $107.20M $71.89M $13.99M $44.42M
Free Cash Flow -$5.94M -$7.59M -$8.85M -$28.39M -$4.92M
Net Other Financing Charges – – – -$527,000.00 –

Discussion

No comments yet — be the first to weigh in on SLS.

Sign in to join the discussion.

Scroll to Top